MAIA Stock Overview
A targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MAIA Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.18 |
| 52 Week High | US$5.99 |
| 52 Week Low | US$0.82 |
| Beta | 0.34 |
| 11 Month Change | -13.15% |
| 3 Month Change | -22.14% |
| 1 Year Change | 127.41% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -51.12% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAIA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.2% | 4.3% | 1.6% |
| 1Y | 127.4% | 18.8% | 32.3% |
Return vs Industry: MAIA exceeded the US Biotechs industry which returned 18% over the past year.
Return vs Market: MAIA exceeded the US Market which returned 32.4% over the past year.
Price Volatility
| MAIA volatility | |
|---|---|
| MAIA Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MAIA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MAIA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 13 | Vlad Vitoc | maiabiotech.com |
MAIA Biotechnology, Inc., a targeted therapy, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc. Fundamentals Summary
| MAIA fundamental statistics | |
|---|---|
| Market cap | US$56.24m |
| Earnings (TTM) | -US$25.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.1x
P/E RatioIs MAIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAIA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$25.94m |
| Earnings | -US$25.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MAIA perform over the long term?
See historical performance and comparison